Name: 溃疡性结肠炎-结直肠癌（UC-CRC）模型评价及柳君子汤（LJZD）疗效
Uploaded: 2023-10-13T12:50:00
Description: Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

evaluation of an ulcerative coloproctitis-colorectal cancer (uc-crc) model and efficacy of liujunzi decoction (ljzd)

六君子汤：预防 UC-CRC 的有效治疗方法

Colorectal cancer (CRC) is a common gastrointestinal malignancy, the third most common malignancy, and the second most common cause of death in the world, accounting for 10% of the global cancer incidence and 9.4% of the total cancer-related death1,2. Genetic factors, chronic inflammation, high-fat diet, diabetes, and abnormal intestinal flora are risk factors for CRC3,4. Among them, inflammatory bowel disease, especially ulcerative coloproctitis (UC), is a clear risk factor for CRC5,6. UC-associated CRC (UC-CRC) is a transition process of inflammation, atypical hyperplasia, and cancer based on chronic inflammation of the colorectum, which is different from the typical adenoma-adenocarcinoma development model of CRC7,8. Compared with the general population, the risk of CRC is approximately 10-40 times higher in patients with inflammatory bowel disease9.
Currently, surgery is still the standard treatment for CRC, and depending on the location and stage of the tumor, radiation therapy, systemic drug therapy, or a combination of both are possible10. Although these traditional treatment modalities have made great progress, due to the high heterogeneity and recurrence rate of CRC, the prognosis is poor, and the treatment effect is not ideal11,12. Therefore, early detection, early diagnosis, and comprehensive treatment are key to improving the survival rate of CRC patients, and it is particularly important to pay attention to the transformation of UC to CRC. Over the years, traditional Chinese medicine (TCM) has attracted much attention in the treatment of UC-CRC or chronic gastritis due to its limited side effects and significant efficacy. Based on dialectical treatment, famous Chinese medicine practitioners of various generations have created a large number of classic prescriptions, such as Huangqi Jianzhong decoction13, Sijunzi decoction14, and Sishen pill15.
Liujunzi decoction (LJZD) originated from the works of Yi Xue Zheng Zhuan compiled in the Ming Dynasty and is a classic prescription in TCM16. As shown in Table 1, LJZD consists of six traditional herbs, including Codonopsis pilosula (Franch.) Nannf. (Dangshen), Poria cocos (Schw.) Wolf (Fuling), Atractylodes macrocephala Koidz. (Baizhu), Glycyrrhiza uralensis Fisch. (Gancao), Citrus reticulata Blanco (Chenpi) and Pinellia ternata (Thunb.) Breit (Banxia), which has the effect of replenishing qi and strengthening the spleen, drying dampness, and resolving phlegm. In modern clinical practice, it is often used to treat chronic gastritis, gastric ulcers, and duodenal ulcers. Modern pharmacological research has shown that LJZD and modified LJZD have high application value in the adjuvant treatment of UC and digestive tract cancer17,18,19.
At present, there are many ways to construct UC-CRC mouse models, but the azoxymethane (AOM)/dextran sulfate sodium (DSS) induced mouse model is the most widely used UC-CRC model; the clinical symptoms, morphological, and pathological observations have proved that the model is very similar to human UC-CRC20,21. The basic principle is to first induce carcinogenesis with chemical carcinogen AOM and then continuously expose mice to the inflammatory stimulation environment of DSS to simulate the continuous damage and repair of intestinal mucosal epithelium, thereby constructing a UC-CRC mouse model22. The aim of this study is to establish a mouse model of UC-CRC by intraperitoneal injection of AOM and cyclic stimulation of DSS in the short term and to evaluate the effect of the drug and the molecular mechanism of LJZD on UC-CRC in order to provide a scientific basis for the treatment of UC-CRC.

作者聚焦： 六君子汤作为结肠直肠炎癌症的中医治疗方法

小鼠结肠直肠炎癌症模型的建立及中药治疗效果评价

This study was on the prevention and treatment of coloproctitis cancer with traditional Chinese medicine. We aim to establish a mouse model for coloproctitis cancer and evaluate traditional Chinese medicine indicators. We confirmed that the Chinese medicine Liujunzi decoction is a effective treatment for coloproctitis cancer prevention.In the future, we will work to identify more sensitive biomarkers for colon and rectal cancer and screen Liujunzi decoction for therapeutic targets.

Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

溃疡性结肠炎-结直肠癌（UC-CRC）模型评价及柳君子汤（LJZD）疗效

首先，建立UC-CRC小鼠模型，并将制备好的LJZD和5-ASA溶液施用于相应的组。药物治疗后，从适应性喂养开始到药物治疗结束，每天监测小鼠的体重。勤奋观察并记录每只实验小鼠的粪便稠度，将其归类为正常，稀便或水样腹泻。仔细记录在实验动物中观察到的任何粪便出血，将其分类为无出血、极少出血或粪便中可见血液。为了分离结直肠组织，将安乐死的小鼠维持在低温解剖环境中。将小鼠固定在仰卧位。用剪刀修剪下腹部毛发并用乙醇对该区域进行消毒。使用眼睑镊，轻轻抓住两个大腿根部和腹部中线之间的交点。然后用剪刀做一个 1 到 1.5 厘米长的横向切口。沿着腹部正中线进行纵向切口，从横切口的中点开始到剑突。小心地将结直肠周围组织朝向肛门的方向分离，将结直肠与周围组织分开。轻轻推开腹部皮肤，使结直肠完全暴露。使用眼睑镊，从腹腔中取出结直肠，并将其从肛门切成盲肠。将收集的结直肠组织保存在4摄氏度的盐水中。与对照组相比，UC-CRC模型组的体重减轻显著，LJZD治疗缓解了体重减轻。与UC-CRC模型组相比，LJZD治疗改善了疾病活动度指数。

Research

JoVE Journal

Medicine

Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer (UC-CRC) Model and Efficacy of Liujunzi Decoction (LJZD)

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading ...